Westchester Capital Management (New York)’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Westchester Capital Management (New York)’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-520,364	Closed	-$5.26M	–	507
2022 Q4	$5.26M	Hold	520,364	–	–	0.14%	163
2022 Q3	$5.17M	Hold	520,364	–	–	0.15%	127
2022 Q2	$5.15M	Hold	520,364	–	–	0.14%	113
2022 Q1	$5.13M	Hold	520,364	–	–	0.14%	117
2021 Q4	$5.12M	Buy	+520,364	New	+$5.11M	0.15%	98

Westchester Capital Management (New York)'s BIOT Position: Q1 2023 in Review

Westchester Capital Management (New York) sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q1 2023, closing a stake of 520,364 shares — an estimated $5.26M sold.

Westchester Capital Management (New York) first reported a position in BIOT in Q4 2021 and held it in 5 quarters. The position peaked at $5.26M in Q4 2022. 0 funds tracked by Wall St. Rank hold BIOT as of Q1 2023.

Westchester Capital Management (New York) reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Westchester Capital Management (New York) sold 520,364 Biotech Acquisition Company Class A Ordinary Shares shares in Q1 2023, an estimated $5.26M.
Westchester Capital Management (New York) first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q4 2021 and held it in 5 quarters.
Westchester Capital Management (New York)'s Biotech Acquisition Company Class A Ordinary Shares position peaked at $5.26M in Q4 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q1 2023.

Based on Westchester Capital Management (New York)'s 13F filing for Q1 2023, filed 15 May 2023.